Myriad Genetics on Monday said insurer Aetna and two other health plans have agreed to cover its Prolaris genetic test that measures tumor cell growth to provide an assessment of how quickly a patient’s prostate cancer may progress. BlueCross BlueShield of Tennessee and a third insurer that Myriad did not identify by name will also...
by Jeff Hansen, University of Alabama at Birmingham Is personalized medicine cost-effective? University of Alabama at Birmingham researcher Nita Limdi, Pharm.D., Ph.D., and colleagues across the United States have answered that question for one medical treatment. Patients experiencing a heart attack—known as a myocardial infarction or an acute coronary syndrome—have sharply diminished blood flow in...
Individuals share about 99.97 percent of their DNA and only the remaining 0.03 percent is responsible for the differences in skin, hair or eye color, height, shoe size or sunspots. Scientists discovered somewhat recently that our bodies also metabolize drugs differently so it would make sense to prescribe medications based on the knowledge hidden in...
